[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lvad-left-ventricular-assist-device\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lvad-left-ventricular-assist-device":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,83,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100592097","compassion-strikes-back-100592097",false,"NCT06988995","Compassion Strikes Back","Compassion Strikes Back: Improving Dyadic Quality of Life for LVAD Patients and Caregivers","Inclusion Criteria:\n\n* LVAD implantation or caregiver or patient with LVAD; over 18 years old; primary caregiver is a family member\n\nExclusion Criteria:\n\n* Currently or in the past 3 months received psychotherapy or psychosocial or peer support; hospitalized for psychiatric reasons in the past 6 months; current, active suicidal thoughts or a reported suicide attempt within the past year; a current alcohol\u002Fsubstance use disorder that required immediate treatment; or a current or past thought disorder, psychosis, or unmanaged bipolar disorder; enrolled in another investigational research\u002Fclinical trial; toxic\u002Fnegative dynamic between pt and caregiver; extended post-LVAD implantation course (i.e., more than 2 months in the hospital).","ALL","18 Years","80 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Research has shown that LVAD patients and their caregivers typically experience increased mental health concerns and decreased quality of life following LVAD implantation and hospital discharge. The purpose of this study is to explore how to improve quality of life for LVAD patients and their caregivers in the initial transition from hospital to home after LVAD implantation.\n\nOver the course of the study, participants will complete 2 surveys: one when participants are in the hospital and one at a 2-month post-hospital follow-up appointment with the participants' cardiologist. Participants may be contacted if there is data missing from surveys.\n\nParticipants may also be provided with information on improving mental health in the form of handouts or a brief meeting with a psychology provider.",[27,28,29,30],"LVAD Caregivers","LVAD (Left Ventricular Assist Device)","Quality of Life (QOL)","Self-Compassion","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2025-12-01",{"date":39,"type":21},"2026-12",{"name":41,"class":42},"University of Florida","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101","NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.",{"count":53,"type":21},370,[55],"PHASE4","This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[58,59,28,60,61,62,63,64,65,66,67,68],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy","Antithrombotic Therapy",[70,59,63,61,62,71,66,72],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":76,"type":35},"2026-06-12",{"date":32,"type":21},{"date":79,"type":21},"2029-12-31",{"name":81,"class":82},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100643643","feasibility-and-clinical-utility-of-ambulatory-ultraslow-deflation-sphygmomanometers-in-lvad-recipients---easislow-lvad-pilot-100643643","NCT07633561","Feasibility and Clinical Utility of Ambulatory Ultraslow Deflation Sphygmomanometers in LVAD Recipients - easiSLOW-LVAD Pilot","easiSLOW-LVAD","Inclusion Criteria:\n\n* HM3 LVAD and age \\> 18\n\nExclusion Criteria:\n\n* eGFR \\\u003C 30\n* bilateral limb alerts (inability to obtain upper extremity blood pressures)\n* ongoing inotropic support\n* cognitive or severe visual impairment\n* the use of an investigational LVAD\n* Durable biventricular support",{"count":91,"type":21},50,[24],"Prospective, single-arm feasibility study will evaluate the use of an ultraslow deflation automated sphygmomanometer (Terumo Elemano 2) for home BP monitoring in patients with continuous-flow LVADs. Outcomes include patient-reported ability to obtain BP readings, adherence, ease of use, and correlation with clinical parameters. Findings may support improved BP monitoring strategies in this high-risk population.",[28],"2026-06-02",{"date":74,"type":35},{"date":98,"type":21},"2026-08-01",{"date":100,"type":21},"2028-02-01",{"name":41,"class":42},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":43},"100600398","cardiac-rehabilitation-cohort-at-the-medicine-campus-davos-to-investigate-recovery-100600398","NCT07096973","Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","RECOVER","Inclusion Criteria:\n\n* Patients undergoing CR at the HGK\n* Written informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation\n* Physical or psychological incapability to participate in the study",{"count":110,"type":21},10000,"10 Years","OBSERVATIONAL","The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension.\n\nThe principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos.\n\nThe study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries.\n\nThe primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up.\n\nRECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.",[115,116,117,118,119,120,28,121,122],"Cardiac Rehabilitation","Heart Failure","Cardiac Arrest (CA)","ACS (Acute Coronary Syndrome)","CABG","Valve Anomalies","Heart Transplantation","Arrhythmia",[124,125],"cardiovascular diseases","cardiac rehabilitation","2025-09-11",{"date":128,"type":35},"2025-09-17",{"date":130,"type":35},"2025-08-05",{"date":132,"type":21},"2040-08-05",{"name":134,"class":42},"Hochgebirgsklinik Davos"]